Full Name | Cameron Phen |
---|---|
Gender | Male |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 688 Cabra St, Lincoln, California |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1750072435 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1223G0001X | Dentist - General Practice | D11858 (Oregon) | Secondary |
390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Cameron Phen, 688 Cabra St, Lincoln, CA 95648-8841 Ph: () - | Cameron Phen, 688 Cabra St, Lincoln, CA 95648-8841 Ph: (916) 899-8386 |
News Archive
The U.S. Food and Drug Administration (FDA) has approved Zolinza (vorinostat) capsules for the treatment of cutaneous T-cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines.
Medisafe 1 Technologies Corp., a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today a significant progress on the discussions to implement the company's safety pre-matching locking device technology for blood transfusion vials with Israel's national Emergency Medical Services Provider who oversee the entire Nation's Blood Banks.
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that it has entered into a definitive agreement to sell its specialty pharmaceutical business to the sigma-tau Group for $300 million plus an additional amount of up to $27 million based on success milestones. Enzon will also receive royalties of 5 to 10 percent on incremental net sales above a 2009 baseline amount from Enzon's four marketed specialty pharmaceutical products through 2014.
Despite the fact that the majority of women presenting to emergency departments for care after sexual assault experience severe pain, very few receive pain treatment. These were the findings of a multi-site research study led by Samuel McLean, MD, MPH, director of the TRYUMPH Research Program in the Department of Anesthesiology at the University of North Carolina School of Medicine. The results were published online in the Journal of Pain on June 15, 2012.
› Verified 4 days ago